Improving Strategies for Cancer Reduction through Early-detection and ENgagement (I-SCREEN)

Leveraging decades of NCI investments in clinical trials, data infrastructure, and cancer screening research, the I-SCREEN (Improving Strategies for Cancer Reduction through Early-detection and ENgagement) ACCESS Hub is well-positioned to efficiently and effectively address pressing issues around the emergence of new technologies for cancer screening. These include evaluating the benefits and harms of new cancer screening technologies and their impacts on cancer-related health disparities. We will build on the University of Colorado Cancer Center's (UCCC) successful administration of large cancer screening trials, including the Prostate, Lung, Ovarian, & Colorectal (PLCO) Cancer Screening Trial and the National Lung Screening Trial (NLST), along with their well-established Colorado Cancer Screening Program (CCSP), a statewide cancer screening network reaching under-resourced communities. UCCC's network of rural health centers will be complemented by Kaiser Permanente Colorado's (KPCO) inclusion of Hispanic members from Colorado's Front Range and extend existing collaborations between UCCC and KPCO in the NCI-funded Colorado Implementation Science Center for Cancer Control (COISC3). We will also build on the synergy between KPCO and Kaiser Permanente Hawaii (KPHI) as the only two sites in NCI's Population-based Research to Optimize the Screen Process (PROSPR) Consortium that are also part of the Connect NCI Cohort Initiative and the Kaiser Permanente (KP) Research Bank (KP's national biobank), both recruiting healthy patients and collecting blood biospecimens. The I-SCREEN Consortium consists of an NCI-designated Cancer Center, two integrated care delivery systems, one federally qualified health system, and one rural critical access hospital system. I-SCREEN will recruit some of the most under-represented populations in clinical trials, including Hispanics, Native Hawaiian/Pacific Islanders (NH/PI), Asian subgroups, and rural populations. Our long-term goal is to reduce cancer-related mortality by rapidly investigating emerging, novel screening technologies in diverse study cohorts to ensure that efficacious new technologies have a broad reach to help decrease, and not widen, cancer-related health disparities. To accomplish this goal, we will: 1) collaborate with NCI, the CSRN Centers and ACCESS Hubs to build an ecosystem to evaluate new cancer screening technologies and strategies in diverse clinical settings; 2) Develop and screening execute the Vanguard feasibility study to inform the design of trials to evaluate new technologies for cancer in under-represented populations; and, 3)increase the impact of CSRN by collaborating with NCI to build a robust data/biospecimen repository available to CSRN investigators and external investigators. Through centralized Administrative, Recruitment and Biospecimens, Engagement, and Data Cores, we will ensure ACCESS Hub collaboration, communication, and progress towards CSRN deliverables. I-SCREEN will be a model for high-impact, translational research to test emerging cancer screening technologies and reduce disparities in cancer mortality.